This is the current revision of this page, as edited by Boghog(talk | contribs) at 18:40, 6 December 2023(added missing chapters to book cites). The present address (URL) is a permanent link to this version.
Revision as of 18:40, 6 December 2023 by Boghog(talk | contribs)(added missing chapters to book cites)
Octatropine methylbromide (INN) or anisotropine methylbromide (USAN), trade names Valpin, Endovalpin, Lytispasm and others,[1] is a muscarinic antagonist and antispasmodic. It was introduced to the U.S. market in 1963 as an adjunct in the treatment of peptic ulcer,[2] and promoted as being more specific to the gastrointestinal tract than other anticholinergics, although its selectivity was questioned in later studies.[3][4]
Octatropine has been superseded by more effective agents in the treatment of peptic ulcer disease, and is no longer used. It is still sold in some countries in combination with other drugs, such as phenobarbital and metamizole.
^Batterman RC, Mouratoff GJ, Kaufman JE (May 1963). "Anisotropine methylbromide: a new antispasmodic for gastrointestinal disorders". Current Therapeutic Research, Clinical and Experimental. 5: 213–218. PMID13966843.